Media
Corgentech Appoints Jack Regan Vice President for Manufacturing
Palo Alto, Calif., March 5, 2003 -- Corgentech Inc., a privately-held biotechnology company, announced today that Jack Regan has been appointed vice president for manufacturing. Mr. Regan joins Corgentech from Genentech, where he served as senior director of manufacturing collaborations.
At Corgentech, he will be responsible for all manufacturing activities, including device engineering, facilities and purchasing. With two Phase III clinical trials underway for E2F Decoy, a treatment for the prevention of graft failure following coronary artery and peripheral bypass surgery, the company is working to assure that its manufacturing activities will support commercialization of its lead product.
"Jack started at Genentech when it was a small, development-stage company and helped them create and manage the most successful and diverse manufacturing operation in the biotechnology industry," said John P. McLaughlin, Corgentech's president and chief executive officer. "With a 22-year career that has included work with drugs, devices and diagnostics, Jack brings a breadth and depth of manufacturing operations experience that will be instrumental to our ability to meet the demands of multiple late-stage clinical trials and our move toward commercialization."
During a 19-year career with Genentech, Regan gained experience with virtually every aspect of manufacturing operations, including: managing numerous facilities involved in all stages of the drug manufacturing process; designing and validating new facilities and expansion of existing facilities; serving as the manufacturing representative during United States Food and Drug Administration inspections and review; identifying, negotiating contracts with, and overseeing operations at drug and device contract manufacturers; and managing the manufacture of Genentech's marketed products.
Prior to Genentech, Mr. Regan was with SmithKline Diagnostics, where he was responsible for the trial formulation, testing and manufacture of medical diagnostics.
He holds a bachelor of science degree from the University of Massachusetts. Mr. Regan is director of the board of Gala Design Inc. and on the editorial advisory board of Contract Pharma Magazine. He is also a member of the Parenteral Drug Association (PDA), International Society of Pharmaceutical Engineering (ISPE) and International Blow Fill Seal Society.
About Corgentech Inc.
Corgentech Inc. is a privately-held biotechnology company that is the leader in the discovery, development and commercialization of an exciting and powerful new class of therapeutics called transcription factor decoys or TF Decoys. The company's proprietary technology platform is capable of delivering multiple new product candidates to treat diseases that affect large patient populations in a relatively short period of time. Corgentech is based in Palo Alto, Calif. For more information, visit www.corgentech.com.
| Contacts: | |
| Richard Powers Corgentech |
Kristin Nash WeissCom Partners |
| 650-624-9600 [email protected] |
415-302-7951 [email protected] |
